Clinical trial · Observational
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
A Multi-Center Study to Evaluate the Guideline Education of Oncology Departments in Small/Middle Tier Cities and County Hospitals for Diagnosis and Treatment Improvement in Patients With Metastatic Non-small Cell Lung Cancer
NCT06494241CI-TRIAL-00113257active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260930-000001
Summary
Brief summary (as posted)
To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bronchial Neoplasms | — | UNRESOLVED | — |
| Carcinoma, Bronchogenic | Bronchogenic Carcinoma | ALIAS | 0.90 |
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Lung Diseases | — | UNRESOLVED | — |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Neoplasms by Site | Neoplasm by Site | ONTOLOGY_EXACT | 0.98 |
| Respiratory Tract Diseases | — | UNRESOLVED | — |
| Respiratory Tract Neoplasms | Respiratory System Neoplasm | ALIAS | 0.90 |
| Thoracic Neoplasms | Thoracic Neoplasm |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP
- timeFrame
- Approximately 1 month after last patient in
- description
- Molecular testing-rate for the first-line treatment: Defined as the number of participants received molecular testing for the first-line treatment divided by total participants.
- measure
- To evaluate the treatment pattern in metastatic NSCLC patients after QIP
- timeFrame
- Approximately 1 month after last patient in
- description
- TKIs first-line treatment rate: Defined as TKIs first-line treatment rate in AGA positive participants.
Secondary outcomes (6)
- measure
- To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
- timeFrame
- Follow up approximately 24 months after last patient in
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years, at the time of signing the informed consent. * ECOG performance status 0-2. * Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC. Exclusion Criteria: * Be participating in other intervention clinical trials. * Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. * Previous enrolment in the other QIP study.
References
Publications (0)
Data not yet available
No reference posted for this study.